Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?

Arthritis and Rheumatism

Volumn 63, Issue 4, 2011, Pages 867-870

  Bendtzen, Klaus ^a,b  

^a Rigshospitalet   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTERY THROMBOSIS; CROHN DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; HUMAN; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; PRIORITY JOURNAL; PROTEOMICS; REMISSION; RHEUMATOID ARTHRITIS; SCREENING; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGENETIC PHENOMENA; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INCIDENCE; METHOTREXATE; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953725136     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30207     Document Type: Editorial

References (17)

1. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7. (Pubitemid 40559296)
2. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 2006;54:3782-9. (Pubitemid 44955878)
3. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
4. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6. (Pubitemid 46999794)
5. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007;6:75-92. (Pubitemid 46020288)
6. Bendtzen K. Immunogenicity of anti-TNF antibodies. In: van de Weert M, Moller EH, editors. Vol. VIII: Immunogenicity of biopharmaceuticals. New York: Springer; 2008. p. 189-203.
7. Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 2008;4:1537-49.
8. Dubey S, Kerrigan N, Mills K, Scott DG. Bronchospasm associated with anti-TNF treatment. Clin Rheumatol 2009;28:989-92.
9. Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011;63:877-83.
10. Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009;19:355-64.
11. Makol A, Grover M, Guggenheim C, Hassouna H. Etanercept and venous thromboembolism: a case series. J Med Case Reports 2010;4:12.
12. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:675-81. (Pubitemid 38296553)
13. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-α binding capacity and anti-infliximab antibodies measured by fluidphase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-8. (Pubitemid 351501078)
14. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of antiantibody measurement. Curr Opin Immunol 2008;20:431-5.
15. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007;46:1828-34. (Pubitemid 350168300)
16. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of antitumour necrosis factor-α antibodies. Scand J Gastroenterol 2009; 44:774-81.
17. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.